(Q46017450)

18 December 2017

title

New paradigms in gastrointestinal stromal tumour management. (English)

1 reference

18 December 2017

author

Jean-Yves Blay

series ordinal

1

1 reference

18 December 2017

publication date

1 May 2009

1 reference

18 December 2017

published in

Annals of Oncology

1 reference

18 December 2017

volume

20 Suppl 1

1 reference

18 December 2017

page(s)

i18-24

1 reference

18 December 2017

Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study.

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP075

Molecular pathobiology of gastrointestinal stromal sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP075

Metastatic gastrointestinal stromal tumors in the era of imatinib: improved survival and elimination of socioeconomic survival disparities

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP075

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP075

Developments in targeted therapy of advanced gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP075

Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP075

An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP075

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP075

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP075

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP075

Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sa

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP075

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP075

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP075

Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP075

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP075

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP075

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP075

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP075

Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP075

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP075

Gastrointestinal stromal tumors: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP075

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDP075

1 reference

18 December 2017

1 reference

18 December 2017